bluebird bio Future Growth
Future criteria checks 2/6
bluebird bio is forecast to grow earnings and revenue by 49% and 41.6% per annum respectively. EPS is expected to grow by 52.8% per annum. Return on equity is forecast to be -21.5% in 3 years.
Key information
49.0%
Earnings growth rate
52.8%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 41.6% |
Future return on equity | -21.5% |
Analyst coverage | Good |
Last updated | 16 Dec 2024 |
Recent future growth updates
Recent updates
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors
Nov 15bluebird bio: Scientific Success And Financial Success, And The Gap Between
Sep 26bluebird bio's Flight Through Financial Fog And Fierce Rivals
Jun 27bluebird bio Is Priced Below IP Value
Mar 23Bluebird Bio: Innovative Therapies, Monetary Setbacks
Jan 25Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Oct 04Bluebird bio names interim finance chief
Sep 26Bluebird bio jumps 17% on FDA approval of new gene therapy
Sep 19bluebird bio' chief strategy and financial officer to depart
Sep 12FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia
Aug 17bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case
Jun 22bluebird bio: Beaten Down Biotech With Possible Long-Term Potential
May 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 311 | -104 | 46 | 64 | 3 |
12/31/2025 | 247 | -115 | -179 | -160 | 9 |
12/31/2024 | 72 | -269 | -315 | -273 | 9 |
9/30/2024 | 53 | -293 | -271 | -264 | N/A |
6/30/2024 | 55 | -319 | -254 | -245 | N/A |
3/31/2024 | 46 | -301 | -248 | -238 | N/A |
12/31/2023 | 29 | -212 | -244 | -235 | N/A |
9/30/2023 | 22 | -63 | -209 | -200 | N/A |
6/30/2023 | 9 | -52 | -236 | -227 | N/A |
3/31/2023 | 4 | -89 | -276 | -262 | N/A |
12/31/2022 | 4 | -230 | -329 | -316 | N/A |
9/30/2022 | 5 | -431 | -447 | -436 | N/A |
6/30/2022 | 6 | -507 | -525 | -506 | N/A |
3/31/2022 | 5 | -563 | -574 | -558 | N/A |
12/31/2021 | 4 | -563 | -659 | -636 | N/A |
9/30/2021 | -238 | -573 | -680 | -651 | N/A |
6/30/2021 | -220 | -614 | -678 | -653 | N/A |
3/31/2021 | -21 | -480 | -493 | -468 | N/A |
12/31/2020 | N/A | -561 | -499 | -470 | N/A |
9/30/2020 | 250 | -642 | -509 | -474 | N/A |
6/30/2020 | 240 | -653 | -493 | -439 | N/A |
3/31/2020 | 54 | -828 | -684 | -616 | N/A |
12/31/2019 | N/A | -555 | -641 | -564 | N/A |
9/30/2019 | 54 | -715 | -611 | -535 | N/A |
6/30/2019 | 57 | -655 | -569 | -496 | N/A |
3/31/2019 | 51 | -605 | -526 | -459 | N/A |
12/31/2018 | 55 | -556 | -469 | -413 | N/A |
9/30/2018 | 40 | -524 | -441 | -379 | N/A |
6/30/2018 | 36 | -457 | N/A | -361 | N/A |
3/31/2018 | 45 | -382 | N/A | -314 | N/A |
12/31/2017 | 35 | -336 | N/A | -281 | N/A |
9/30/2017 | 33 | -290 | N/A | -254 | N/A |
6/30/2017 | 27 | -288 | N/A | -237 | N/A |
3/31/2017 | 11 | -276 | N/A | -228 | N/A |
12/31/2016 | 6 | -264 | N/A | -190 | N/A |
9/30/2016 | 6 | -239 | N/A | -154 | N/A |
6/30/2016 | 6 | -205 | N/A | -143 | N/A |
3/31/2016 | 9 | -198 | N/A | -111 | N/A |
12/31/2015 | 14 | -167 | N/A | -98 | N/A |
9/30/2015 | 19 | -139 | N/A | -81 | N/A |
6/30/2015 | 24 | -113 | N/A | -73 | N/A |
3/31/2015 | 25 | -63 | N/A | -72 | N/A |
12/31/2014 | 25 | -49 | N/A | -60 | N/A |
9/30/2014 | 25 | -37 | N/A | -49 | N/A |
6/30/2014 | 25 | -26 | N/A | -38 | N/A |
3/31/2014 | 25 | -29 | N/A | -35 | N/A |
12/31/2013 | 20 | -25 | N/A | 43 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLUE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLUE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLUE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLUE's revenue (41.6% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: BLUE's revenue (41.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLUE is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 08:51 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
bluebird bio, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jack Allen | Baird |
Huidong Wang | Barclays |
Zhiqiang Shu | Berenberg |